VYTORIN | US Patents | Expiry | Expiration | Dates | PharmaCompass.com

Please Wait

Applying Filters...

Grow Your Pharma Business Digitally

Find Suppliers : API/FDF
- Search Our Integrated Database
Services
Excipients
Drugs in Dev.
News
Blog
Market Place
Login

VYTORIN
US Patents

EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

Contact Supplier

SPI Pharma has been solving formulation challenges using superior functional materials.

Contact Supplier

Interquim comes from an international group of 50 companies active in the pharma, hospital, diagnostics, fine chemicals & feed sectors.

Contact Supplier

Cohance Lifesciences, offers full range of CDMO services for small molecule APIs, intermediates, ADCs, Pellets and Formulations.

Contact Supplier

FAMAR CDMO- From early development to commercial manufacturing.

Contact Supplier

Polfa Tarchomin is a leading Polish pharmaceutical company with 200 year tradition in manufacture and sale of pharmaceutical products.

Contact Supplier

VYTORIN

ACCESS ALL DATA, CHEMISTRY

ACCESS ALL DATA
Browse all information
CHEMISTRY
Discover Molecule Insights

ACTIVE PHARMA INGREDIENTS

77 API Suppliers, 29 USDMF, 11 JDMF, 17 EU WC, 63 KDMF, 18 NDC API, 50 Listed Suppliers, $ API Reference Price

77 API Suppliers
29 USDMF
11 JDMF
17 EU WC
63 KDMF
18 NDC API
50 Listed Suppliers
$ API Reference Price

DEVELOPMENTS

20 Drugs in Development

20 Drugs in Development

INTERMEDIATES

34 Intermediate Suppliers

34 Intermediate Suppliers

FINISHED DOSAGE FORMULATIONS

595 FDF Dossiers, 66 FDA Orange Book, 356 Europe, 22 Canada, 23 Australia, 27 South Africa, 101 Listed Dossiers

595 FDF Dossiers
66 FDA Orange Book
356 Europe
22 Canada
23 Australia
27 South Africa
101 Listed Dossiers

DRUG PRODUCT COMPOSITIONS

TABLET;ORAL - EQ 10MG BASE;10MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, TABLET;ORAL - EQ 20MG BASE;10MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, TABLET;ORAL - EQ 40MG BASE;10MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, TABLET;ORAL - EQ 80MG BASE;10MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, TABLET;ORAL - 10MG, TABLET;ORAL - 10MG;10MG, TABLET;ORAL - 10MG;20MG, TABLET;ORAL - 10MG;40MG, TABLET;ORAL - 10MG;80MG

TABLET;ORAL - EQ 10MG BASE;10MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
TABLET;ORAL - EQ 20MG BASE;10MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
TABLET;ORAL - EQ 40MG BASE;10MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
TABLET;ORAL - EQ 80MG BASE;10MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
TABLET;ORAL - 10MG
TABLET;ORAL - 10MG;10MG
TABLET;ORAL - 10MG;20MG
TABLET;ORAL - 10MG;40MG
TABLET;ORAL - 10MG;80MG

RELATED EXCIPIENT COMPANIES

2 Minakem, 6 SPI Pharma, 4 DKSH, 6 Faran Shimi Pharmaceutical, 5 Boai NKY Pharmaceuticals Ltd, 1 Chynops Pharma, 6 Gangwal Healthcare, 2 Nanjing Well Pharmaceutical, 1 Pramukh Pharmachem, 1 ACG Worldwide, 1 Aeon Procare, 2 Alcedo Pharmachem, 10 Anhui Sunhere Pharmaceutical Excipients Co.,Ltd, 19 BASF, 10 Corel Pharma Chem, 7 DFE Pharma, 8 Gangwal Chemicals, 5 Ideal Cures Pvt Ltd, 4 Ingredion Pharma Solutions, 36 Kerry, 3 Kima Chemical, 6 Lonza Capsugel, 13 Microlex e.U, 1 NEWEDGE Overseas, 3 Novo Excipients, 5 Pharmatrans-Sanaq, 6 Pluviaendo, 5 Prachin Chemical, 1 Qianhao Chemical (Hebei) Co., Ltd, 1 Qualicaps, 18 Roquette, 7 Seppic, 5 Shanghai Shenmei Pharmaceutical Technology Co., Ltd, 12 Sigachi Industries, 2 The Dow Chemical Company, 1 Ulanqab Kema New Material, 4 Vasa Pharmachem

EXCIPIENTS BY APPLICATIONS

65 Fillers, Diluents & Binders, 47 Coating Systems & Additives, 41 Disintegrants & Superdisintegrants, 29 Direct Compression, 27 Granulation, 24 Controlled & Modified Release, 22 Lubricants & Glidants, 17 Thickeners and Stabilizers, 11 Chewable & Orodispersible Aids, 11 Co-Processed Excipients, 9 Taste Masking, 9 Solubilizers, 9 Film Formers & Plasticizers, 6 API Stability Enhancers, 5 Coloring Agents, 5 Empty Capsules, 4 Vegetarian Capsules, 4 Emulsifying Agents, 4 Parenteral, 3 Rheology Modifiers, 2 Topical, 1 Surfactant & Foaming Agents

65 Fillers, Diluents & Binders
47 Coating Systems & Additives
41 Disintegrants & Superdisintegrants
29 Direct Compression
27 Granulation
24 Controlled & Modified Release
22 Lubricants & Glidants
17 Thickeners and Stabilizers
11 Chewable & Orodispersible Aids
11 Co-Processed Excipients
9 Taste Masking
9 Solubilizers
9 Film Formers & Plasticizers
6 API Stability Enhancers
5 Coloring Agents
5 Empty Capsules
4 Vegetarian Capsules
4 Emulsifying Agents
4 Parenteral
3 Rheology Modifiers
2 Topical
1 Surfactant & Foaming Agents

DIGITAL CONTENT

111 NEWS #PharmaBuzz

111 NEWS #PharmaBuzz

GLOBAL SALES INFORMATION

3 US Medicaid Prescriptions, 329 Finished Drug Prices, 38 Annual Reports

3 US Medicaid Prescriptions
329 Finished Drug Prices
38 Annual Reports

MARKET PLACE

20 APIs, 5 FDF Dossiers

20 APIs
5 FDF Dossiers

PATENTS & EXCLUSIVITIES

19 US Patents, 3 US Exclusivities, 2 Health Canada Patents

19 US Patents
3 US Exclusivities
2 Health Canada Patents

REF. STANDARDS & IMPURITIES

2 USP, 2 Others

2 USP
2 Others

ANALYTICAL

6 BioAnalytical Methods

6 BioAnalytical Methods

$ API Ref.Price (USD/KG) : 1,320 Xls

Filters

Reset all filters

Filters

FILTER :

filter Applicant Reset all filters

19 All

01 8ALTHERA PHARMS

02 8ESPERION THERAPS INC

03 3ORGANON

filter Patent Number Reset all filters

19 All

01 17335799

02 27612058

03 49763885

04 410376470

05 210912751

06 111613511

07 211744816

08 111760714

09 111926584

10 17612058*PED

filter API Patent Reset all filters

19 All

01 2Y

02 17Blank

filter FDF Patent Reset all filters

19 All

01 9Y

02 10Blank

filter Expiration Date Reset all filters

19 All

01 22025-10-30

02 12026-04-30

03 12030-12-03

04 82033-05-01

05 42036-03-14

06 32040-06-19

Product Main Page

01

ALTHERA PHARMS

EZETIMIBE; ROSUVASTATIN CALCIUM

PharmScience R&D

Not Confirmed

ALTHERA PHARMS

PharmScience R&D

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2033-05-01

EZETIMIBE; ROSUVASTATIN CALCIUM

US Patent Number : 10376470

Drug Substance Claim :

Drug Product Claim : Y

Application Number : 213072

Patent Use Code : U-3095

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2033-05-01

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

02

ALTHERA PHARMS

EZETIMIBE; ROSUVASTATIN CALCIUM

PharmScience R&D

Not Confirmed

ALTHERA PHARMS

PharmScience R&D

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2033-05-01

EZETIMIBE; ROSUVASTATIN CALCIUM

US Patent Number : 9763885

Drug Substance Claim :

Drug Product Claim : Y

Application Number : 213072

Patent Use Code : U-3095

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2033-05-01

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

03

ALTHERA PHARMS

EZETIMIBE; ROSUVASTATIN CALCIUM

PharmScience R&D

Not Confirmed

ALTHERA PHARMS

PharmScience R&D

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2033-05-01

EZETIMIBE; ROSUVASTATIN CALCIUM

US Patent Number : 9763885

Drug Substance Claim :

Drug Product Claim : Y

Application Number : 213072

Patent Use Code : U-3095

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2033-05-01

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

04

ALTHERA PHARMS

EZETIMIBE; ROSUVASTATIN CALCIUM

PharmScience R&D

Not Confirmed

ALTHERA PHARMS

PharmScience R&D

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2033-05-01

EZETIMIBE; ROSUVASTATIN CALCIUM

US Patent Number : 10376470

Drug Substance Claim :

Drug Product Claim : Y

Application Number : 213072

Patent Use Code : U-3095

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2033-05-01

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

05

ALTHERA PHARMS

EZETIMIBE; ROSUVASTATIN CALCIUM

PharmScience R&D

Not Confirmed

ALTHERA PHARMS

PharmScience R&D

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2033-05-01

EZETIMIBE; ROSUVASTATIN CALCIUM

US Patent Number : 10376470

Drug Substance Claim :

Drug Product Claim : Y

Application Number : 213072

Patent Use Code : U-3095

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2033-05-01

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

06

ALTHERA PHARMS

EZETIMIBE; ROSUVASTATIN CALCIUM

PharmScience R&D

Not Confirmed

ALTHERA PHARMS

PharmScience R&D

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2033-05-01

EZETIMIBE; ROSUVASTATIN CALCIUM

US Patent Number : 9763885

Drug Substance Claim :

Drug Product Claim : Y

Application Number : 213072

Patent Use Code : U-3095

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2033-05-01

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

07

ALTHERA PHARMS

EZETIMIBE; ROSUVASTATIN CALCIUM

PharmScience R&D

Not Confirmed

ALTHERA PHARMS

PharmScience R&D

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2033-05-01

EZETIMIBE; ROSUVASTATIN CALCIUM

US Patent Number : 10376470

Drug Substance Claim :

Drug Product Claim : Y

Application Number : 213072

Patent Use Code : U-3095

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2033-05-01

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

08

ALTHERA PHARMS

EZETIMIBE; ROSUVASTATIN CALCIUM

PharmScience R&D

Not Confirmed

ALTHERA PHARMS

PharmScience R&D

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2033-05-01

EZETIMIBE; ROSUVASTATIN CALCIUM

US Patent Number : 9763885

Drug Substance Claim :

Drug Product Claim : Y

Application Number : 213072

Patent Use Code : U-3095

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2033-05-01

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

09

ESPERION THERAPS INC

BEMPEDOIC ACID; EZETIMIBE

PharmScience R&D

Not Confirmed

ESPERION THERAPS INC

PharmScience R&D

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2036-03-14

BEMPEDOIC ACID; EZETIMIBE

US Patent Number : 11744816

Drug Substance Claim :

Drug Product Claim :

Application Number : 211617

Patent Use Code : U-3883

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2036-03-14

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

10

ESPERION THERAPS INC

BEMPEDOIC ACID; EZETIMIBE

PharmScience R&D

Not Confirmed

ESPERION THERAPS INC

PharmScience R&D

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2036-03-14

BEMPEDOIC ACID; EZETIMIBE

US Patent Number : 10912751

Drug Substance Claim :

Drug Product Claim :

Application Number : 211617

Patent Use Code : U-3884

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2036-03-14

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

1
2

Contact us
to update this info

Privacy policy
Terms and conditions
Disclaimers
ASK US!